Response to: “Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test”

Weiland, Thomas; Brčić, Luka; Reinholz, Markus; French, Lars E.; Thurnher, Dietmar

doi:10.1016/j.ebiom.2020.103139

Cited by 3 publications

(4 citation statements)

References 2 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings indicate that the dominance of IgG at the time of diagnosis might play a role in further risk-stratification of HPV-positive OPSCCs. Relapse was in three of three cases associated with an increase of HPV-L1-IgG beforehand, which, on the other hand, would support the conclusion of our previous study that HPV-L1 antibody detection might be used as a post-treatment biomarker [ 14 , 15 ]…”

Section: Discussionsupporting

confidence: 79%

“…The HPV L1 related antibody response was generally seen as a marker of cumulative HPV infection, unsuitable for tumor diagnostics. As part of our previous study, however, we were able to show immunohistochemically that HPV-associated tumors express HPV L1 and we further illustrated that antibody titers in most cases reflect the course of disease [ 14 , 15 ]. We have also shown in individual cases that an increase in the HPV-L1 antibody titer could indicate a possible recurrence of the disease [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 73%

See 1 more Smart Citation

Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study

Weiland,

Zgubic,

Brcic

et al. 2024

Eur Arch Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

Purpose Despite prognostic superiority of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), up to 25% of patients will suffer from recurrence within the first 5 years. Therefore, it is of great scientific interest to find relevant biomarkers to identify patients at risk. In this prospective observational study, we aimed to investigate the dynamics of HPV-L1 capsid protein specific antibody (AB) subclasses IgA, IgM, and IgG in HPV-positive OPSCC patients under therapy. Methods Serum samples from HPV-positive OPSCC patients, identified by positive p16-immunohistochemistry, were collected before and during tumor-specific therapy and 3–6 months during follow-up. They were analyzed for the presence of HPV-L1 AB subclasses IgA, IgM, and IgG using an HPV-L1-specific immuno-assay. Additionally, a PCR-based HPV-DNA detection from the tumor tissue was performed. Results Altogether, 33 patients with a mean follow-up of 55 months were included. Analysis of a total of 226 serum samples revealed that the most common L1-AB-subclass pattern was characterized by IgG > > IgA > IgM without significant fluctuation during the course of disease. Patients with excessive IgG levels tended to higher tumor stages and three out of three patients with disease recurrence showed increasing IgG AB titers beforehand. Seven patients showed an IgA dominance at diagnosis, which was associated with a better disease-free survival. Conclusion Despite limited cases, our prospective pilot study revealed promising trends in HPV L1 AB subclasses and may contribute useful information for future risk stratification and post-treatment monitoring in HPV-positive OPSCC patients.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 73%

Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study

Weiland,

Zgubic,

Brcic

et al. 2024

Eur Arch Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since it is known that immune responses are important not only concerning the development of tumors but also for prognostic information, an important question is what role the immune system plays in the success of therapy and to what extent the immune response can be mapped (15). In a previous study, we prospectively examined OPSCC patients with a subtype-speci c competitive serological assay based on an HPV16-L1-speci c monoclonal antibody (AB) before and after therapy, showing that antibody titers in most cases re ect the course of disease (16,17). We have also shown in individual cases that an increase in the HPV-L1 antibody titer could indicate a possible recurrence of the disease (16,17).…”

Section: Introductionmentioning

confidence: 99%

“…In a previous study, we prospectively examined OPSCC patients with a subtype-speci c competitive serological assay based on an HPV16-L1-speci c monoclonal antibody (AB) before and after therapy, showing that antibody titers in most cases re ect the course of disease (16,17). We have also shown in individual cases that an increase in the HPV-L1 antibody titer could indicate a possible recurrence of the disease (16,17).…”

Section: Introductionmentioning

confidence: 99%

Survival benefit for HPV+ OPSCC patients with dominant serum IgA over IgG antibodies against HPV16 L1

Weiland,

Zgubic,

Brcic

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Although the therapy response of HPV-positive oropharyngeal carcinomas (OPSCC) is known to be significantly better compared to HPV-negative tumors, about 25% of them will have a recurrence within the first 5 years after therapy. Therefore, it is of great scientific interest to find relevant biomarkers to identify subgroups with a poorer prognosis. In this prospective observational study, we examine for the first time the behavior of HPV-L1 antibody subclasses IgA, IgG, and IgM in HPV-positive OPSCC patients under therapy. Material and Methods The study cohort included patients with HPV-positive OPSCCs from the Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Graz. Serum samples were collected before and during tumor-specific therapy and follow-up. They were analyzed for the presence of HPV-L1 antibody (AB) subclasses IgA, IgM, and IgG using an HPV-L1-specific immuno-assay. In addition, a PCR-based HPV-DNA detection and subtyping from the tumor tissue was performed. Statistical analysis included Chi2- and Kruskal-Wallis-H-Test for significance testing. Correlation between two ordinal sizes has been tested using Spearmen-Rho. Results Altogether, 34 patients with a mean age of 63.5 years and a mean follow-up of 55 months were included. The most common L1-AB-subclass pattern was characterized by IgG > > IgA > IgM (13 cases) without significant fluctuation. The second most common pattern was IgG > IgA > IgM (6 cases). In 5 cases an antibody pattern of IgA > IgG > IgM while in 4 cases IgG = IgA > IgM was seen. Three out of 4 recurrences had previously shown an increase in IgG antibodies. Patients with excessive IgG levels tended to have higher tumor stages. IgA dominance at diagnosis was associated with better disease-free survival. Conclusions In this prospective longitudinal observational study, we show for the first time the behavior of HPV-L1 antibody subclasses IgA, IgG, and IGM in HPV-positive OPSCC patients under therapy. IgA dominance at diagnosis was associated with better disease-free survival, whereas a higher IgG/IgA ratio correlated with higher tumor stages. In three recurrent tumors, an increase in the IgG AB level could be shown beforehand. HPV-L1 AB-subclass detection might be of use for future risk stratification in HPV-pos. OPSCC patients.

show abstract

High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study

et al. 2022

View full text Add to dashboard Cite

Response to: “Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test”

Cited by 3 publications

References 2 publications

Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study

Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study

Survival benefit for HPV+ OPSCC patients with dominant serum IgA over IgG antibodies against HPV16 L1

High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study

Contact Info

Product

Resources

About